Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients
Table 1
Characteristics of breast cancer patients included in the study () and treatment parameters.
Characteristic
Category/Unit
(%)
Age
Years
50.9 (42.1-59.1)
Type of surgery
Mastectomy
48 (47.5)
Conservative surgery
53 (52.5)
Side of surgery
Left
48 (47.5)
Right
53 (52.5)
Tumour type
Invasive lobular carcinoma
2 (2.0)
Invasive ductal carcinoma
96 (95.0)
Other
3 (3.0)
Cancer grade
1
1 (1.0)
2
31 (30.7)
3
69 (68.3)
Chemotherapy scheme
AC/EC/FAC/FEC with taxanes
54 (53.5)
AC/EC/FAC/FEC without taxanes
43 (42.6)
Other
4 (4.0)
Anthracyclines
Yes
99 (98.0)
Doxorubicin
6 (6.0)
Epirubicin
93 (92.1)
No
2 (2.0)
Anthracyclines cumulative dose
Doxorubicin, mg/m2 BSA
342 (318-413)
Epirubicin, mg/m2 BSA
353 (294-522)
Taxanes
Yes
58 (57.4)
Paclitaxel
17 (16.7)
Docetaxel
41 (40.6)
No
43 (42.6)
Taxanes cumulative dose
Paclitaxel, mg/m2 BSA
886 (739-938)
Docetaxel, mg/m2 BSA
286 (269-299)
Hormonal therapy
Yes
57 (56.4)
No
44 (43.6)
Treatment scheme of RT
84 (83.2)
17 (16.8)
Site of RT
Breast/mammary region
58 (57.4)
(Breast/mammary region) + regional lymph nodes
43 (42.6)
RT technique
2D RT
80 (79.2)
3D CRT
14 (13.9)
Electrons
7 (6.9)
Hypertension
Yes
29 (28.7)
No
72 (71.3)
Hyperlipidemia
Yes
21 (20.8)
No
80 (79.2)
Smoking
Yes
16 (15.8)
No
85 (84.2)
Diabetes
Yes
1 (1.0)
No
100 (99.0)
Body mass index
kg/m2
27.1 (24.3-29.7)
median (25%-75%). 2D RT: two-dimensional radiotherapy; 3D CRT: three-dimensional conformal radiotherapy; AC: doxorubicin, cyclophosphamide; BSA: body surface area calculated according to the Du Bois formula; EC: epirubicin, cyclophosphamide; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; Gy: Gray; RT: radiotherapy.